Baseline and disease characteristics
| Characteristic . | Value . |
|---|---|
| Age, median (range), y | 33 (18-78) |
| Sex, n (%) | |
| Male | 142 (60.9) |
| Female | 90 (38.6) |
| Not available | 1 (0.4) |
| Ethnic origin, n (%) | |
| White | 143 (61.4) |
| Black | 25 (10.7) |
| Hispanic | 27 (11.6) |
| Asian and Pacific Islander | 9 (3.9) |
| Native American/Alaska Native | 1 (0.4) |
| Other | 5 (2.1) |
| Not available | 23 (9.9) |
| BMI, median (range), kg/m2 | 26.9 (23.2-31.2) |
| ECOG performance status, n (%) | |
| 0 | 105 (45.1) |
| 1 | 93 (39.9) |
| 2 | 27 (11.6) |
| 3 | 5 (2.1) |
| Not available | 3 (1.3) |
| Smoking status, n (%) | |
| Current smoker | 23 (9.9) |
| Former smoker | 54 (23.2) |
| Never smoker | 152 (65.2) |
| Not available | 4 (1.7) |
| Medical comorbidities/VTE and bleeding risk factors, n (%) | |
| Obesity | 46 (19.7) |
| Renal failure | 6 (2.6) |
| Heart disease | 15 (6.4) |
| Respiratory disease | 7 (3.0) |
| Bleeding condition | 6 (2.6) |
| Other cancers | 16 (6.9) |
| Active infection | 14 (6.0) |
| Menstrual suppression in induction | 15 (6.4) |
| Therapeutic anticoagulation | 11 (4.7) |
| Other | 11 (4.7) |
| Laboratory data at diagnosis, median (range) | |
| WBC, ×109/L | 14.4 (4.7-76.0) |
| Fibrinogen, mg/dL | 393 (270-552) |
| AT level, %∗ | 100 (86-108) |
| ALL disease status, n (%) | |
| Newly diagnosed | 219 (94.0) |
| Relapsed/refractory | 12 (5.2) |
| Not available | 2 (0.9) |
| Type of ALL, n (%) | |
| B-cell ALL | 157 (67.4) |
| T-cell ALL | 72 (30.9) |
| NK-cell ALL | 2 (0.9) |
| Mixed phenotype | 2 (0.9) |
| Cytogenetics, n (%) | |
| Normal | 47 (20.2) |
| t(9;22) (Philadelphia chromosome) | 17 (7.3) |
| Standard risk cytogenetics† | 17 (7.3) |
| Poor risk cytogenetics† | 26 (11.2) |
| Other | 43 (18.5) |
| Not tested or not available | 83 (35.6) |
| Characteristic . | Value . |
|---|---|
| Age, median (range), y | 33 (18-78) |
| Sex, n (%) | |
| Male | 142 (60.9) |
| Female | 90 (38.6) |
| Not available | 1 (0.4) |
| Ethnic origin, n (%) | |
| White | 143 (61.4) |
| Black | 25 (10.7) |
| Hispanic | 27 (11.6) |
| Asian and Pacific Islander | 9 (3.9) |
| Native American/Alaska Native | 1 (0.4) |
| Other | 5 (2.1) |
| Not available | 23 (9.9) |
| BMI, median (range), kg/m2 | 26.9 (23.2-31.2) |
| ECOG performance status, n (%) | |
| 0 | 105 (45.1) |
| 1 | 93 (39.9) |
| 2 | 27 (11.6) |
| 3 | 5 (2.1) |
| Not available | 3 (1.3) |
| Smoking status, n (%) | |
| Current smoker | 23 (9.9) |
| Former smoker | 54 (23.2) |
| Never smoker | 152 (65.2) |
| Not available | 4 (1.7) |
| Medical comorbidities/VTE and bleeding risk factors, n (%) | |
| Obesity | 46 (19.7) |
| Renal failure | 6 (2.6) |
| Heart disease | 15 (6.4) |
| Respiratory disease | 7 (3.0) |
| Bleeding condition | 6 (2.6) |
| Other cancers | 16 (6.9) |
| Active infection | 14 (6.0) |
| Menstrual suppression in induction | 15 (6.4) |
| Therapeutic anticoagulation | 11 (4.7) |
| Other | 11 (4.7) |
| Laboratory data at diagnosis, median (range) | |
| WBC, ×109/L | 14.4 (4.7-76.0) |
| Fibrinogen, mg/dL | 393 (270-552) |
| AT level, %∗ | 100 (86-108) |
| ALL disease status, n (%) | |
| Newly diagnosed | 219 (94.0) |
| Relapsed/refractory | 12 (5.2) |
| Not available | 2 (0.9) |
| Type of ALL, n (%) | |
| B-cell ALL | 157 (67.4) |
| T-cell ALL | 72 (30.9) |
| NK-cell ALL | 2 (0.9) |
| Mixed phenotype | 2 (0.9) |
| Cytogenetics, n (%) | |
| Normal | 47 (20.2) |
| t(9;22) (Philadelphia chromosome) | 17 (7.3) |
| Standard risk cytogenetics† | 17 (7.3) |
| Poor risk cytogenetics† | 26 (11.2) |
| Other | 43 (18.5) |
| Not tested or not available | 83 (35.6) |
Data are presented as n (%) or median (interquartile range), unless otherwise stated.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; NK, natural killer; WBC, white blood cell.
Only evaluated in 68 patients.
Cytogenetic risk stratification is based on the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (version 4.2023).